Related Experiment Videos
Plasma cyclic adenosine 3',5'-monophosphate (cAMP) levels in hyperthyroid patients
Experimental and Clinical Endocrinology
|August 1, 1983
Summary
Plasma cyclic adenosine monophosphate (cAMP) levels are elevated in hyperthyroidism and normalize after treatment with propylthiouracil, indicating a link between thyroid hormones and cAMP signaling.
Area of Science:
- Endocrinology
- Molecular Biology
- Metabolic Research
Background:
- Hyperthyroidism is a condition characterized by excessive thyroid hormone production.
- Cyclic adenosine monophosphate (cAMP) is a crucial second messenger involved in various cellular processes.
- The relationship between thyroid hormone levels and plasma cAMP in hyperthyroidism requires further elucidation.
Purpose of the Study:
- To investigate plasma cyclic adenosine monophosphate (cAMP) levels in hyperthyroid patients.
- To assess the effect of propylthiouracil treatment on plasma cAMP levels.
- To explore the correlation between plasma iodothyronine and cAMP levels during treatment.
Main Methods:
- Measurement of plasma cyclic AMP levels in ten hyperthyroid subjects.
- Analysis of cAMP levels before and after propylthiouracil treatment.
- Monitoring of plasma iodothyronine levels to assess treatment efficacy.
Main Results:
- Untreated hyperthyroid subjects exhibited significantly elevated plasma cAMP levels.
- Propylthiouracil treatment led to a normalization of plasma cAMP levels.
- Normalized cAMP levels correlated with the decline of plasma iodothyronine into the normal range.
Conclusions:
- Plasma cAMP levels are significantly elevated in hyperthyroidism.
- Propylthiouracil effectively reduces plasma cAMP levels in hyperthyroid patients.
- Thyroid hormone levels directly influence plasma cAMP, suggesting a role in hyperthyroid pathophysiology.